Search Results
Your search for ,wHo matches 21223 pages
Showing 7351 - 7400Global Burden of Cervical Cancer and Association With HIV
A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...
Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers
A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...
Ganglioside Vaccine Plus β-Glucan for Patients With High-Risk Neuroblastoma and Prior Disease Progression
In a single-institution phase II study reported in the Journal of Clinical Oncology, Cheung et al found that a subcutaneous ganglioside G2/G3 vaccine plus oral β-glucan produced antibody responses in patients with high-risk neuroblastoma, with higher anti–GD2-IgG1 titers being associated with...
Neoadjuvant Chemotherapy and Overall Survival in Metastatic Endometrial Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Tobias et al found that receipt of neoadjuvant chemotherapy was associated with improved short-term but not long-term survival vs primary debulking surgery in patients with metastatic endometrial cancer. As stated by the...
GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths
On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
NIH RADx-rad Grants Support Investigation of Novel COVID-19 Testing and Surveillance Approaches
The National Institutes of Health (NIH) has awarded over $107 million to support new, nontraditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program will also develop platforms that can be deployed in future outbreaks of COVID-19...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
In an observational cohort study reported in JAMA Oncology, Catherine H. Van Poznak, MD, FASCO, and colleagues found that the 3-year incidence of osteonecrosis of the jaw was 2.8% among patients with cancer receiving zoledronic acid for metastatic bone disease. Shorter dosing interval, fewer teeth, ...
CMS Increases Access to Telemedicine in Home Health Care
The Centers for Medicare & Medicaid Services (CMS) recently released its Home Health Prospective Payment System final rule for 2021. The final rule reflects comments ASCO submitted on the proposed rule in support of increased access to telemedicine in home health care and concerns over home...
The Heart of Catherine Handy Marshall, MD, MPH’s Work
In 2017, Women Who Conquer Cancer (WWCC) awarded Catherine Handy Marshall, MD, MPH, a Conquer Cancer Young Investigator Award (YIA) grant to explore the impact of cardiovascular disease risk factors on cancer outcomes. Three years after receiving the WWCC YIA, Dr. Handy Marshall is pursuing...
Increase Your Knowledge and Practice of Cultural Competence With ASCO eLearning Course Collection
“Equity: Every Patient. Every Day. Everywhere” was selected by 2020–2021 ASCO President Lori J. Pierce, MD, FASTRO, FASCO, as the theme for her presidential term. As oncology care providers work to put this theme into practice, they can find support in ASCO eLearning’s new Cultural Literacy course...
Intensity of Active Surveillance in Patients With Rectal Cancer Managed With a Watch-and-Wait Approach
In a study reported in The Lancet Oncology, Fernandez et al found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained clinical complete response to neoadjuvant chemotherapy for 1, 3, or 5 years. Study Details In the...
Pembrolizumab Plus Chemotherapy for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, pembrolizumab (Keytruda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer with tumors expressing PD-L1 (Combined ...
Roswell Park Experts Named to Highly Cited Researchers List
Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have...
Susan E. Hankinson, ScD, MPH, Receives AACR Distinguished Lectureship in Breast Cancer Research Award
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) honored Susan E. Hankinson, ScD, MPH, for her significant contributions to breast cancer research. Dr. Hankinson received the 2020 AACR Distinguished Lectureship in Breast Cancer Research award...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
John Ryan, JD, Named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has appointed John Ryan, JD, as its Senior Vice President, General Counsel, and Chief Governance Officer. Mr. Ryan has extensive expertise representing health-care and life sciences organizations in public company and nonprofit settings. He has managed a wide range of...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
FDA Approves Adjuvant Osimertinib for EGFR-Mutated NSCLC
On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...
Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASTRO’s Red Journal
The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...
City of Hope Physician Joins Carol Emmott Fellowship
Lorna Rodriguez-Rodriguez, MD, PhD, Vice Chair of Faculty Development at City of Hope, is among 21 women leaders in the nation who were invited to join the Carol Emmott Fellowship Class of 2021, a 14-month program for “exceptional, innovative women leaders who are making lasting change in their...
2020 Basser Global Prize Awarded to Bella Kaufman, MD, of Israel’s Sheba Medical Center
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania recently announced Bella Kaufman, MD, of the Sheba Medical Center in Tel-Hashomer, Israel, as the recipient of the eighth annual Basser Global Prize. Dr. Kaufman is Director of the Breast Oncology Institute,...
Rutgers Researcher Receives $400K Grant to Examine Racial Health Disparities in Cancer Care
Anita Kinney, PhD, MSN, Professor at the Rutgers School of Public Health and Associate Director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is among 10 recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to...
ASH Recognizes Choosing Wisely Champions at Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions, practitioners working to tackle overuse of hematology tests and treatments, at the all-virtual 2020 ASH Annual Meeting & Exposition. Choosing Wisely, a program of the ABIM Foundation and Consumer Reports, aims...
European Experts Tackle HPV-Related Cancers
The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...
Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win
Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...
Addressing Inequality in Cancer Care on a Global Scale
It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...
IU Simon Researcher Receives $1.3 Million Grant to Improve Breast Cancer Treatment for Black Women
Harikrishna Nakshatri, PhD, who is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer, received a $1.3 million grant from the Department of Defense–Congressionally Directed Medical Research Program’s breast cancer research program. Dr. -Nakshatri...
Intratumoral Injections May Boost Neoadjuvant Response in Resectable Melanoma
Studies reported at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which was held virtually, showed promise for the use of intratumoral injections of novel immunotherapies in treating advanced, resectable melanoma. In the 3-year interim analysis of a global phase II randomized...
Novel Combination Under Study in First-Line Treatment of Metastatic Melanoma
A first-line regimen combining the novel interleukin-2 (Il-2) agonist bempegaldesleukin (NKTR-214) with nivolumab showed encouraging clinical activity in patients with metastatic melanoma in the phase I/II PIVOT-02 trial, according to a presentation during the 2020 Annual Meeting of the Society for ...
Expert Point of View: Karen M. Winkfield, MD, PhD
Moderator of the session, Karen M. Winkfield, MD, PhD, a radiation oncologist at Vanderbilt University Medical Center, and Executive Director of the Meharry-Vanderbilt Alliance in Nashville, underscored the importance of approaching patient survivorship holistically. “As radiation oncologists,...
Sexual Health: An Issue for Many Survivors of Cancer
Sexual dysfunction is prevalent among cancer survivors—and rarely addressed—according to data presented during the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 A survey of cancer survivors has found that nearly 9 out of 10 respondents reported some change after cancer...
Expert Point of View: Laura Dawson, MD
Laura Dawson, MD, Professor of Radiation Oncology at the University of Toronto and Princess Margaret Cancer Centre, viewed these initial study results as “a strong signal with high promise.” “Radiation therapy improves local control and delays local disease progression in patients with pancreatic...
Novel Radiomodulation Approach With Dismutase Mimetic Plus SBRT in Resectable Pancreatic Cancer
Pancreatic cancer is one of the most aggressive, lethal malignancies, and life-extending treatments represent a critical unmet need. A pilot study suggests a potential way forward for patients with nonmetastatic unresectable or borderline resectable pancreatic cancer may be a combination of...
Pralsetinib for RET-Altered Thyroid Cancers
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2020, pralsetinib (Gavreto) was granted...
CTC Enumeration Predicts Survival Early in Treatment of Metastatic Breast Cancer
The number of circulating tumor cells (CTCs) assessed at baseline and at about 1 month after cancer-directed treatment was strongly associated with overall survival in patients with metastatic breast cancer, according to a large retrospective pooled analysis reported at the 2020 San Antonio Breast...
Edith Mitchell, MD, Elected to Fellowship in the Royal College of Physicians of London
Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center–Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London (RCP). The RCP was founded in 1518 by a Royal Charter from King Henry VIII. RCP...
ASH Registry: Treasure Trove of Data on COVID-19 and Hematologic Malignancies
The ASH Research Collaborative COVID-19 Registry for Hematology provides up-to-date information on outcomes and the course of illness for a group of patients with hematologic malignancies and COVID-19.1 In general, registry data showed that hematologic malignancies increase the risk of severity of...
Expert Point of View: Jacob Soumerai, MD
“CAPTIVATE is a very important study,” stated Jacob Soumerai, MD, Associate Professor at Harvard Medical School and Massachusetts General Hospital Cancer Center. “The take-home point is that this [ibrutinib plus venetoclax] is highly effective therapy and achieves a high rate of undetectable...
Fixed-Duration First-Line Ibrutinib Plus Venetoclax Yields Treatment-Free Remission in Some Patients With CLL
The randomized phase II CAPTIVATE trial showed that a fixed-duration treatment approach with 12 cycles of ibrutinib and venetoclax as first-line therapy for chronic lymphocytic leukemia (CLL) achieved a 30-month progression-free survival of more than 95% in patients with undetectable minimal...
Ruxolitinib Improves Outcomes in Patients With Steroid-Refractory or Steroid-Dependent Graft-vs-Host Disease
Ruxolitinib was superior to best available therapy in achieving efficacy as determined by best overall response and duration of response, with acceptable safety in adolescents and adults with steroid-dependent or steroid-refractory chronic graft-vs-host disease effects. These findings were shown in ...
Cancer Survivor Offers Roadmap for Managing the Turmoil of Diagnosis and Treatment
Although the field of psychosocial oncology had its roots in the 1970s, it wasn’t until 2007 that the Institute of Medicine acted on the growing data describing the impact of emotional well-being and physical recovery on quality of life, establishing guideline standards requiring that the...
Challenges Related to Informed Consent and Information-Sharing for Minors With Cancer
Here we discuss a complex and often emotionally wrenching challenge related to informed consent in the provision of pediatric cancer care. For example, what legal and ethical claims do young patients have to information about their cancer diagnosis and treatment recommendations? What are the...
Initial Therapy for Asymptomatic Follicular Lymphoma: Start With Watch and Wait or Rituximab
For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic, advised John P. Leonard, MD, Executive Vice-Chair of Weill Department of Medicine at Weill-Cornell Medicine/NewYork-Presbyterian, New York.1 “Prognostic scores are...
RxPONDER: Many Postmenopausal Patients With Node-Positive Breast Cancer Can Avoid Chemotherapy
Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage hormone receptor–positive, HER2-negative breast cancer and node-positive disease.1 The data showed that many postmenopausal women can skip adjuvant chemotherapy, based on ...
2020 FDA Approvals of Drugs for Cancer Treatment
Over the past year (January to December 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in oncology and hematology. A brief review of new approvals appears here. For complete prescribing information for ...
